Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Comanche Biopharma
AddedFeb 15, 2024
UpdatedJun 18, 2026
Comanche Biopharma

Comanche Biopharma

Comanche Biopharma develops siRNA therapies for safer pregnancies and fetal maturation.

HQ
Concord, MA, US
Founded
2020
Overview
Compare
Fundraising
Employees
Website

Comanche Biopharma is a biopharmaceutical company focused on developing siRNA therapies to treat preeclampsia, aiming to make pregnancies safer and allow for proper fetal maturation. Their mission is to create globally accessible treatments targeting the root causes of preeclampsia, reducing risks associated with pregnancy and prematurity.

Comanche Biopharma has made significant strides in preclinical development, working towards the first investigational siRNA medicine for preterm preeclampsia. Their vision is to ensure all women and their babies have access to safe, effective, and evidence-based therapies for life-threatening pregnancy complications.

Comanche Biopharma - Similar Companies

Nextrna Therapeutics logo

Nextrna Therapeutics

Sirnaomics logo

Sirnaomics

sirnaomics.com

Chimeron Bio logo

Chimeron Bio

Cambrian BioPharma logo

Cambrian BioPharma

cambrianbio.com

CAMP4 Therapeutics logo

CAMP4 Therapeutics

camp4tx.com

Locanabio logo

Locanabio

TenSixteen Bio logo

TenSixteen Bio

Cadenza Bio logo

Cadenza Bio

cadenza.bio

Katana Pharmaceuticals logo

Katana Pharmaceuticals

Traversa Therapeutics logo

Traversa Therapeutics

traversathera.com

Aldena Therapeutics logo

Aldena Therapeutics

Commence Bio logo

Commence Bio

Cargene logo

Cargene

cargene.com

Faze Medicines logo

Faze Medicines

fazemed.com

CiVi Biopharma logo

CiVi Biopharma

civibio.com

Comanche Biopharma - Quick Facts

Who are Comanche Biopharma's competitors?

Companies similar to Comanche Biopharma include Nextrna Therapeutics, Sirnaomics, Chimeron Bio and Cambrian BioPharma.

When was Comanche Biopharma founded?

Comanche Biopharma was founded in 2020.

Where is Comanche Biopharma's headquarters located?

Comanche Biopharma's headquarters is located in Concord, MA, US.

When was Comanche Biopharma's last funding round?

Comanche Biopharma's most recent funding round was for $75M (USD) in January 2024.

How much has Comanche Biopharma raised to-date?

As of Jan 17, 2024, Comanche Biopharma has raised a total of $111.1M (USD).

How many employees does Comanche Biopharma have?

Comanche Biopharma has 14 employees as of Feb 5, 2024.

Comanche Biopharma - Classification

Ownership
  • Private
  • Venture Capital
Technology
  • Biotech
  • Sirna
Geographic Exposure
  • Global
Revenue
  • Recurring
Customer
  • Enterprise
Main Product
  • Therapeutics
NAICS
  • 540000Professional, Scientific, and Technical Services
  • 541714Research and Development in Biotechnology (except Nanobiotechnology)
  • 541000Professional, Scientific, and Technical Services
  • 541700Scientific Research and Development Services
  • 541710Research and Development in the Physical, Engineering, and Life Sciences
SIC
  • 8700Engineering, Accounting, Research, Management, And Related Services
  • 8730Research, Development, And Testing Services
  • 8731Commercial Physical and Biological Research
Show 12 more industry codes
NAICS
  • 320000Manufacturing
  • 325400Pharmaceutical and Medicine Manufacturing
  • 620000Health Care and Social Assistance
  • 325000Chemical Manufacturing
  • 325410Pharmaceutical and Medicine Manufacturing
  • 325412Pharmaceutical Preparation Manufacturing
SIC
  • 2800Chemicals And Allied Products
  • 8000Health Services
  • 2830Drugs
  • 8040Offices And Clinics Of Other Health Practitioners
  • 2834Pharmaceutical Preparations
  • 8049Offices And Clinics Of Health Practitioners, Not Elsewhere Classified